X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
BIO89-100 (pegozafermin) is a specifically engineered glycoPEGylated analog of fibroblast growth factor 21 (FGF21) being developed for the treatment of metabolic dysfunction-associated steatohepatitis & severe hypertriglyceridemia.
Lead Product(s): Pegozafermin
Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Product Name: BIO89-100
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 27, 2024
Details:
89bio candidate BIO89-100 (pegozafermin), an FGF-21 agonist. Currently, It is being evaluated in the Phase II clinical trial studies for the treatment of Non-Cirrhotic Metabolic Dysfunction-Associated Steatohepatitis with Fibrosis.
Lead Product(s): Pegozafermin
Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Product Name: BIO89-100
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 12, 2024
Details:
The proceeds will be used to fund ongoing clinical activities and development of BIO-89-100 (pegozafermin), a specifically engineered glycoPEGylated analog of fibroblast growth factor 21 (FGF21), manufacturing scale-up.
Lead Product(s): Pegozafermin
Therapeutic Area: Cardiology/Vascular Diseases Product Name: BIO89-100
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: BofA Securities
Deal Size: $172.5 million Upfront Cash: Undisclosed
Deal Type: Public Offering December 12, 2023
Details:
The proceeds will be used to fund ongoing clinical activities and development of BIO-89-100 (pegozafermin), a specifically engineered glycoPEGylated analog of fibroblast growth factor 21 (FGF21), manufacturing scale-up.
Lead Product(s): Pegozafermin
Therapeutic Area: Cardiology/Vascular Diseases Product Name: BIO-89-100
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: BofA Securities
Deal Size: $150.0 million Upfront Cash: Undisclosed
Deal Type: Public Offering December 07, 2023
Details:
BIO89-100 (pegozafermin) is a fibroblast growth factor 21 (FGF21) analog which is being developed for the treatment of nonalcoholic steatohepatitis (NASH) and severe hypertriglyceridemia (SHTG).
Lead Product(s): Pegozafermin
Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Product Name: BIO89-100
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 27, 2023
Details:
BIO89-100 (pegozafermin) is a specifically engineered glycoPEGylated analog of fibroblast growth factor 21 (FGF21) being developed for the treatment of non-alcoholic steatohepatitis (NASH) and severe hypertriglyceridemia (SHTG).
Lead Product(s): Pegozafermin
Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Product Name: BIO89-100
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 21, 2023
Details:
BIO89-100 (pegozafermin) is a specifically engineered glycoPEGylated analog of fibroblast growth factor 21 (FGF21) being developed for the treatment of non-alcoholic steatohepatitis (NASH) and severe hypertriglyceridemia (SHTG).
Lead Product(s): Pegozafermin
Therapeutic Area: Cardiology/Vascular Diseases Product Name: BIO89-100
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 23, 2023
Details:
89bio intends to use the net proceeds from this offering to fund ongoing clinical activities and development of BIO89-100 (pegozafermin), manufacturing scale-up and other general corporate purposes.
Lead Product(s): Pegozafermin
Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Product Name: BIO89-100
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: BofA Securities
Deal Size: $275.0 million Upfront Cash: Undisclosed
Deal Type: Public Offering March 24, 2023
Details:
BIO89-100 (pegozafermin) is a specifically engineered glycoPEGylated analog of fibroblast growth factor 21 (FGF21) being developed for the treatment of non-alcoholic steatohepatitis (NASH) and severe hypertriglyceridemia (SHTG).
Lead Product(s): Pegozafermin
Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Product Name: BIO89-100
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 22, 2023
Details:
BIO89-100 (pegozafermin), is a specifically engineered glycoPEGylated analog of fibroblast growth factor 21 (FGF21) being developed for the treatment of non-alcoholic steatohepatitis (NASH) and severe hypertriglyceridemia (SHTG).
Lead Product(s): Pegozafermin
Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Product Name: BIO89-100
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 12, 2022
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
